Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

TOBRAMYCIN & DEXAMETHASONE

All products: general benefit

TobraDex · DIN 00778915 · 0.3% & 0.1% · Oph Oint

General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
TobraDex · DIN 00778915 Manufacturer: Novartis Pharma Canada Inc.; listing date 1996-10-01 Health Canada: Marketed since 2018-04-26 · brand TOBRADEX · ATC S01CA01 DEXAMETHASONE AND ANTIINFECTIVES · form Ointment · route Ophthalmic · ingredients TOBRAMYCIN 0.3 %/W/W, DEXAMETHASONE 0.1 %/W/W · company Novartis pharmaceuticals canada inc · schedule Prescription
Check this DIN again · Health Canada product record

TobraDex: Formulary list price $3.3171/unit (unit not stated in source; not the patient's cost)

Ministry pays: $3.3171 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10971 · Verify on the e-Formulary ↗ (DIN 00778915)

Source record
DIN 00778915: TobraDex Raw flags: sec3=Y Item: 520404032; group id 585; item number 1541; lccId None; manufacturer id NOV Source form: Oph Oint; strength: 0.3% & 0.1% Recorded listing: General benefit Source prices (unrounded): $3.3171; ministry $3.3171 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00778915 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10971
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (52:04:04 Antibiotics) and how they are covered

Matched class: 52:04:04 Antibiotics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: FRAMYCETIN SULFATE, FRAMYCETIN SULFATE & GRAMICIDIN & DEXAMETHASONE, GENTAMICIN & BETAMETHASONE SODIUM PHOSPHATE, GENTAMICIN SULFATE, POLYMYXIN B SULFATE & BACITRACIN (ZINC), POLYMYXIN B SULFATE & GRAMICIDIN, TOBRAMYCIN 52:04:04 Antibiotics

FRAMYCETIN SULFATE

· 2 products · General benefit · strengths: 0.5% · Oph Oint-5g Pk, Oph Sol

FRAMYCETIN SULFATE & GRAMICIDIN & DEXAMETHASONE

· 1 products · General benefit · strengths: 5mg & 50mcg & 0.5mg/mL · Oph/Ot Sol

GENTAMICIN & BETAMETHASONE SODIUM PHOSPHATE

· 1 products · General benefit · strengths: 3mg & 1mg/mL · Oph/Ot Drops

GENTAMICIN SULFATE

· 1 products · General benefit · strengths: 0.3% · Oph Oint-3.5g Pk

POLYMYXIN B SULFATE & BACITRACIN (ZINC)

· 1 products · General benefit · strengths: 10000U & 500U/g · Oph Oint 3.5g Pk

POLYMYXIN B SULFATE & GRAMICIDIN

· 1 products · General benefit · strengths: 10000U & 0.025mg/mL · Oph/Ot Sol

TOBRAMYCIN

· 3 products · General benefit · strengths: 0.3% · Oph Oint, Oph Sol

CIPROFLOXACIN AND DEXAMETHASONE

· 3 products · Limited Use, codes 509 · strengths: 0.3% w/v & 0.1% w/v · Otic Susp-7.5mL Pk (With Preservative)

GATIFLOXACIN

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 0.3% w/v · Oph Sol

MOXIFLOXACIN HYDROCHLORIDE

· 8 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 0.5% · Oph Sol-3mL Pk (Preservative-Free) Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 52:04:04
Full class listing Related classes: 52:04:12 Other Anti-Infectives, 52:08:92 Anti-Inflammatory Agents, Miscellaneous Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE TOBRADEX® (tobramycin and dexamethasone ophthalmic suspension and ointment) is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exist. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation, thermal burns or penetration of foreign bodies. To reduce the development of drug-resistant bacteria and maintain the effectiveness of TOBRADEX and other antibacterial drugs, TOBRADEX should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. Pediatrics (< 18 years of age): The safety and effectiveness of TOBRADEX have not been established in pediatric patients. TOBRADEX® Product Monograph Page 3 of 28 https://pdf.hres.ca/dpd_pm/00055027.PDF PM date: February 12, 2020 Source product: TOBRADEX; DIN 00778907; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.